ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Long-term Hormonal Therapy Adds No Additional Benefits

September 27, 2013

Bush Appoints Seven to NCAB, Designates Runowicz as Chairman.

July 28, 2006

In Brief: CREG To Be Used In Viral Oncology, Nutrition, Cell Kinetics, Immunology, Rauscher Tells NCAB

April 4, 1975

Oncology Nursing Foundation Offers Research Fellowship, Clinical Scholar Award

September 29, 1995

NCI New Advisory Group Named On special Populations

June 25, 1999

PET Response Can Predict Increased Survival In Patients

April 27, 2012